Core Points - GENFIT, a biopharmaceutical company, focuses on improving the lives of patients with rare and life-threatening liver diseases and has filed its 2024 Universal Registration Document and Annual Report on Form 20-F [1][2] Company Overview - GENFIT is dedicated to addressing unmet medical needs in liver diseases, particularly Acute-on-Chronic Liver Failure (ACLF), with a diverse R&D portfolio that includes five assets under development: VS-01, G1090N, SRT-015, CLM-022, and VS-02-HE [2] - The company has a strong history in liver disease research, with over two decades of experience and expertise in developing high-potential molecules, evidenced by the accelerated approval of Iqirvo (elafibranor) for Primary Biliary Cholangitis (PBC) [2] - GENFIT also has a diagnostic franchise targeting Metabolic dysfunction-associated steatohepatitis (MASH) and blood ammonia levels [2] Financial Reporting - The 2024 Universal Registration Document and the Annual Report on Form 20-F are publicly available for free on GENFIT's website and the websites of the AMF and SEC [2][5] - The annual financial report includes the annual management report, Board of Directors' report on corporate governance, and Statutory Auditors' reports on financial statements [4]
GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F